Avatrombopag Reduced Procedure-Related Transfusions in Thrombocytopenia, Chronic Liver Disease Patients

Findings from two international, randomized, double-blind, phase III, placebo-controlled trials published in the September issue of Gastroenterology revealed that the oral second-generation thrombopoietin agonist avatrombopag (Doptelet) when given once a day, notably decreased the requirement for platelet transfusion...

• Source: MDEdge
• 932
• August 3, 2018